688319.SHG Chengdu Olymvax Biopharmaceuticals Inc. A

Healthcare Biotechnology Shanghai Stock Exchange
28.20 CNY
Close of Nov 4, 2026
20.41 44.90
Market cap
CNY 11.4B
P/E
-
P/B
12.60x
ROE
-7.6%
Dividend yield
0.13%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688319.SHG undervalued?

Graham number

The Graham number of Chengdu Olymvax Biopharmaceuticals Inc. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chengdu Olymvax Biopharmaceuticals Inc. A fundamental analysis

No fundamental analysis for Chengdu Olymvax Biopharmaceuticals Inc. A yet.

Chengdu Olymvax Biopharmaceuticals Inc. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chengdu Olymvax Biopharmaceuticals Inc. A

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

Full company profile